Regular use of aspirin was associated with a 2-fold greater risk of developing the neovascular subtype of age-related macular degeneration (AMD) than in non-users.
Regular use of aspirin was associated with a 2-fold greater risk of developing the neovascular subtype of age-related macular degeneration (AMD) than in non-users, according to research reported online in JAMA Internal Medicine.
Australian researchers’ finding of a longitudinal association-with temporal information in the association, ie, exposure to aspirin before the development of AMD-confirms an observation from a European cross-sectional survey (European Eye Study) that also reported a 2-fold higher prevalence of neovascular AMD among regular aspirin users compared with non-users (Ophthalmology. 2011;119:112–118).
“The reported association from the European Eye Study, however, lacked temporal information as the exposure and the disease outcome were measured simultaneously in the survey,” Paul Mitchell, MD, PhD, principal investigator of the study, called the Blue Mountains Eye Study (BMES), told Formulary. “Nevertheless, this confirmation suggests a consistency of the evidence on this association in 2 different population-based samples. We felt that it would be important to see if there is a longitudinal association present between regular use of aspirin and subsequent development of AMD. As the BMES had such longitudinal data available, we acted on this project without delay.”
Evidence from observational studies can usually only generate and/or support a study hypothesis but cannot resolve completely the controversy of the study question or hypothesis, mainly due to the lack of a proven mechanism(s) for the associations from observational studies, said Dr Mitchell, who is also professor in ophthalmology and director of the Westmead Millennium Institute’s Centre for Vision Research, Sydney, Australia.
The research team conducted a population-based study of 2,389 older Australians aged 50+ years 2 decades ago (1992-1994). They followed this sample over 15 years with 5-year intervals between each examination, and collected a range of data including retinal photographs from study participants.
“We defined incident AMD using retinal photographic documentation with verification. We collected information on aspirin use via face-to-face interviews in multiple study visits. We used statistical models to assess the link between the 2 while adjusting for possible confounding factors that were also collected in our study, the Blue Mountains Eye Study,” Dr Mitchell said.
While aspirin is among the most effective cardiovascular disease (CVD) preventive therapies to reduce recurrent CVD events (secondary prevention), regular use over the longer term has been associated with a number of well-documented adverse side effects such as increased gastrointestinal, intracerebral, and extracranial hemorrhage. “If our finding is further replicated by other studies, the possibility of a deleterious effect on vision via an increase in the risk of AMD needs to also be considered for patients who are at high risk of AMD [eg, existing neovascular AMD in the other eye], in addition to other known adverse effects,” Dr Mitchell said.
“Given the widespread use of aspirin, any increased risk of disabling conditions and morbidity would likely be important and may affect small subgroups of patients, in this case, patients who are at high risk of neovascular AMD,” he said. “However, the magnitude of this potential risk is relatively small-9.3% after 15 years-and needs to be balanced with the significant morbidity and mortality of suboptimally treated CVD.”
Currently there is insufficient evidence to recommend changing clinical practice, except perhaps in cases of patients with strong risk factors for neovascular AMD, in whom it could be appropriate to raise awareness among the patients and families of the potentially small, but increased, risk of incident neovascular AMD in patients on long-term aspirin therapy, according to Dr Mitchell.
“The increased risk of neovascular AMD was only detected after 10 or 15 years. This may suggest that cumulative dosage of aspirin may be important in pathogenesis,” he said.
“Our findings also suggest the specificity of the association: only aspirin use (but not other pain killers) was associated with neovascular AMD-but not associated with the early stage of AMD or geographic atrophy, another subtype of late-stage AMD,” Dr Mitchell concluded.
Coalition promotes important acetaminophen dosing remindersNovember 18th 2014
It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance designJune 30th 2014
The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacyJune 13th 2013
Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomesJune 12th 2013
I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
2 Clarke Drive
Cranbury, NJ 08512